Deferasirox

Generic Name: Deferasirox

Brand Names: Exjade, Jadenu, 恩瑞格, Deferasirox Accord, Deferasirox Mylan

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₅N_₃O_₄

CAS Number: 201530-41-8

Unique Ingredient Identifier: V8G4MOF2V9

Background: Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.

Indication: For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

Associated Conditions: Chronic Iron Overload

Associated Therapies: -

Clinical Trials

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Phase 2

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Placebo
Drug: Deferasirox

First Posted Date: 2009-07-16

Last Posted Date: 2020-11-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 225

Registration Number: NCT00940602

Locations: 🇺🇸
Willis-Knighton Cancer Center Dept of Onc, Shreveport, Louisiana, United States
🇺🇸
Hackensack University Medical Center Department of Research, Hackensack, New Jersey, United States
🇺🇸
Rocky Mountain Cancer Centers RMCC, Greenwood Village, Colorado, United States

and more 9 locations

Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec

Phase 2

Completed

Conditions: Beta Thalassemia Transfusion Dependent

Interventions: Drug: Deferasirox

First Posted Date: 2009-04-09

Last Posted Date: 2016-12-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT00879242

Locations: 🇮🇹
Novartis Investigative Site, Orbassano, Italy

Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study

Phase 2

Completed

Conditions: Non-transfusion Dependent Thalassemia

Interventions: Drug: deferasirox
Drug: placebo

First Posted Date: 2009-04-01

Last Posted Date: 2013-07-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 166

Registration Number: NCT00873041

Locations: 🇺🇸
Children's Memorial Hospital/Division of Hematology/Oncology, Chicago, Illinois, United States
🇺🇸
New York Presbyterian Hospital/Weill Medical College of Cornell University, New York, New York, United States
🇺🇸
Children's Hospital & Research Center Oakland, Oakland, California, United States

and more 1 locations

Pilot Study for Patients With Poor Response to Deferasirox

Phase 4

Completed

Conditions: Transfusion-dependent Hemachromatosis
Sickle Cell Disease
Thalassemia Major

Interventions: Drug: Deferoxamine
Drug: Deferasirox
Radiation: HIDA

First Posted Date: 2008-09-09

Last Posted Date: 2024-02-12

Lead Sponsor: Boston Children's Hospital

Target Recruit Count: 15

Registration Number: NCT00749515

Locations: 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States

Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both

Phase 1

Conditions: Thalassemia

Interventions: Drug: Deferoxamine
Drug: Deferasirox

First Posted Date: 2008-08-20

Last Posted Date: 2010-11-05

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 6

Registration Number: NCT00738413

Locations: 🇺🇸
Weill Cornell Medical Center, New York, New York, United States

Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload

Phase 4

Completed

Conditions: Hemoglobinopathies
Myelodysplastic Syndromes
Other Inherited or Acquired Anaemia
MPD Syndrome
Diamond-Blackfan Anemia
Other Rare Anaemias
Transfusional Iron Overload

Interventions: Drug: deferasirox

First Posted Date: 2008-05-07

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis

Target Recruit Count: 118

Registration Number: NCT00673608

Locations: 🇦🇺
Novarts Investigative Site, Sydney, Australia

Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload

Phase 4

Completed

Conditions: Iron Overload

Interventions: Drug: Deferasirox

First Posted Date: 2008-04-08

Last Posted Date: 2016-11-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 75

Registration Number: NCT00654589

Locations: 🇩🇪
Novartis Investigative Site, Leipzig, Germany

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

Phase 2

Terminated

Conditions: Breast Cancer
Iron Overload
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Neuroblastoma
Ovarian Cancer

Interventions: Drug: deferasirox

First Posted Date: 2008-01-28

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 4

Registration Number: NCT00602446

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload

Phase 2

Completed

Conditions: Transfusional Iron Overload
Transfusional Hemosiderosis

Interventions: Drug: Deferasirox
Drug: Deferoxamine

First Posted Date: 2008-01-25

Last Posted Date: 2014-08-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 197

Registration Number: NCT00600938

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda

Phase 3

Completed

Conditions: Porphyria Cutanea Tarda

Interventions: Drug: Deferasirox

First Posted Date: 2008-01-23

Last Posted Date: 2014-02-10

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 10

Registration Number: NCT00599326

Locations: 🇺🇸
UT Southwestern Medical Center at Dallas - Dermatology Clinical Trials, Dallas, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy